4521 Stock Overview
Produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Kaken Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥4,021.00 |
52 Week High | JP¥4,217.00 |
52 Week Low | JP¥3,161.00 |
Beta | 0.27 |
11 Month Change | 6.07% |
3 Month Change | 18.65% |
1 Year Change | 15.12% |
33 Year Change | -18.02% |
5 Year Change | -24.28% |
Change since IPO | 67.54% |
Recent News & Updates
Shareholder Returns
4521 | JP Pharmaceuticals | JP Market | |
---|---|---|---|
7D | -1.3% | 0.4% | -2.3% |
1Y | 15.1% | 18.3% | 21.1% |
Return vs Industry: 4521 underperformed the JP Pharmaceuticals industry which returned 18.3% over the past year.
Return vs Market: 4521 underperformed the JP Market which returned 21.1% over the past year.
Price Volatility
4521 volatility | |
---|---|
4521 Average Weekly Movement | 3.3% |
Pharmaceuticals Industry Average Movement | 3.9% |
Market Average Movement | 3.7% |
10% most volatile stocks in JP Market | 7.3% |
10% least volatile stocks in JP Market | 1.8% |
Stable Share Price: 4521 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4521's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1917 | 1,135 | Hiroyuki Horiuchi | www.kaken.co.jp |
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; and Salinomycin, an anti-coccidial feed additive for chickens.
Kaken Pharmaceutical Co., Ltd. Fundamentals Summary
4521 fundamental statistics | |
---|---|
Market cap | JP¥152.54b |
Earnings (TTM) | JP¥8.03b |
Revenue (TTM) | JP¥72.04b |
19.0x
P/E Ratio2.1x
P/S RatioIs 4521 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4521 income statement (TTM) | |
---|---|
Revenue | JP¥72.04b |
Cost of Revenue | JP¥33.51b |
Gross Profit | JP¥38.54b |
Other Expenses | JP¥30.51b |
Earnings | JP¥8.03b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 07, 2024
Earnings per share (EPS) | 211.91 |
Gross Margin | 53.49% |
Net Profit Margin | 11.14% |
Debt/Equity Ratio | 2.7% |
How did 4521 perform over the long term?
See historical performance and comparisonDividends
3.7%
Current Dividend Yield190%
Payout RatioDoes 4521 pay a reliable dividends?
See 4521 dividend history and benchmarksKaken Pharmaceutical dividend dates | |
---|---|
Ex Dividend Date | Sep 27 2024 |
Dividend Pay Date | Dec 02 2024 |
Days until Ex dividend | 65 days |
Days until Dividend pay date | 131 days |
Does 4521 pay a reliable dividends?
See 4521 dividend history and benchmarks